GRAIL, Inc. Share-based Payment Arrangement, Expense, after Tax
GRAIL, Inc. (GRAL) reported Share-based Payment Arrangement, Expense, after Tax of $44.58 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2026-03-12
- GRAIL, Inc. share-based payment arrangement, expense, after tax for the quarter ending 2025-12-31 was $5.99M, a 41.81% decline year-over-year.
- GRAIL, Inc. share-based payment arrangement, expense, after tax for the quarter ending 2025-09-30 was $13.50M, a 2.14% increase year-over-year.
- GRAIL, Inc. share-based payment arrangement, expense, after tax for the quarter ending 2025-06-30 was $13.27M, a 32.47% decline year-over-year.
- GRAIL, Inc. share-based payment arrangement, expense, after tax for the quarter ending 2025-03-31 was $11.82M, a 46.38% decline year-over-year.
- GRAIL, Inc. share-based payment arrangement, expense, after tax for fiscal 2025 was $44.58M, a 31.63% decline from fiscal 2024.
- GRAIL, Inc. share-based payment arrangement, expense, after tax for fiscal 2024 was $65.19M, a 11.64% decline from fiscal 2023.
- GRAIL, Inc. share-based payment arrangement, expense, after tax for fiscal 2023 was $73.78M, a 27.91% increase from fiscal 2023.
- GRAIL, Inc. share-based payment arrangement, expense, after tax for fiscal 2023 was $57.68M.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $19.49M derived: sum of 2 quarters · filed 2026-03-12 | $32.76M derived: sum of 3 quarters · filed 2026-03-12 | $44.58M 10-K · filed 2026-03-12 |
| 2025-09-30 | $13.50M 10-Q · filed 2025-11-13 | $26.77M derived: sum of 2 quarters · filed 2025-11-13 | $38.59M 10-Q · filed 2025-11-13 | $48.88M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | $13.27M 10-Q · filed 2025-08-13 | $25.09M 10-Q · filed 2025-08-13 | $35.38M derived: sum of 3 quarters · filed 2026-03-12 | $48.59M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $11.82M 10-Q · filed 2025-05-14 | $22.11M derived: sum of 2 quarters · filed 2026-03-12 | $35.33M derived: sum of 3 quarters · filed 2026-03-12 | $54.97M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | $10.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $23.51M derived: sum of 2 quarters · filed 2026-03-12 | $43.16M derived: sum of 3 quarters · filed 2026-03-12 | $65.19M 10-K · filed 2026-03-12 |
| 2024-09-30 | $13.22M 10-Q · filed 2025-11-13 | $32.87M derived: sum of 2 quarters · filed 2025-11-13 | $54.90M 10-Q · filed 2025-11-13 | $73.76M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $19.65M 10-Q · filed 2025-08-13 | $41.69M 10-Q · filed 2025-08-13 | $60.54M derived: sum of 3 quarters · filed 2026-03-12 | $79.75M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $22.04M 10-Q · filed 2025-05-14 | $40.90M derived: sum of 2 quarters · filed 2026-03-12 | $60.11M derived: sum of 3 quarters · filed 2026-03-12 | $79.49M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $18.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $38.07M derived: sum of 2 quarters · filed 2026-03-12 | $57.45M derived: sum of 3 quarters · filed 2026-03-12 | $73.78M 10-K · filed 2025-03-05 |
| 2023-09-30 | $19.21M 10-Q · filed 2024-11-13 | $38.60M derived: sum of 2 quarters · filed 2024-11-13 | $54.92M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $19.39M 10-Q · filed 2024-08-13 | $35.71M 10-Q · filed 2024-08-13 | ||
| 2023-01-01 | $57.68M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |